

BIOMARIN PHARMACEUTICAL INC

Form 4

October 23, 2007

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Wood Mark

2. Issuer Name and Ticker or Trading  
Symbol  
BIOMARIN PHARMACEUTICAL  
INC [BMRN]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
10/22/2007

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_X\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)  
VP, Human Resources

C/O BIOMARIN  
PHARMACEUTICAL INC., 105  
DIGITAL DRIVE

(Street)

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_X\_\_\_\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

NOVATO, CA 94949

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D)	Price	
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	M		521	A \$ 6.37	521 D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	M		177	A \$ 6.13	698 D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	M		521	A \$ 11.74	1,291 D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	M		313	A \$ 14	1,532 D
	10/22/2007 <sup>(1)</sup>	10/22/2007	S		154	D \$ 25	1,378 D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common  
Stock

Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	S	153	D	\$ 25.1901	1,225	D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	S	153	D	\$ 25.3001	1,072	D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	S	306	D	\$ 25.3101	766	D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	S	153	D	\$ 25.33	613	D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	S	154	D	\$ 25.36	459	D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	S	153	D	\$ 25.3701	306	D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	S	153	D	\$ 25.3901	153	D
Common Stock	10/22/2007 <sup>(1)</sup>	10/22/2007	S	153	D	\$ 25.46	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (right to buy)	\$ 6.37	10/22/2007 <sup>(1)</sup>	10/22/2007	M		521		11/03/2004 <sup>(2)</sup>	05/02/2014	Common Stock	521

Common Stock (right to buy)	\$ 6.13	10/22/2007 <sup>(1)</sup>	10/22/2007	M	177	07/07/2005 <sup>(3)</sup>	01/06/2015	Common Stock	177
Common Stock (right to buy)	\$ 11.74	10/22/2007 <sup>(1)</sup>	10/22/2007	M	521	07/06/2006 <sup>(4)</sup>	01/05/2016	Common Stock	521
Common Stock (right to buy)	\$ 14	10/22/2007 <sup>(1)</sup>	10/22/2007	M	313	12/21/2006 <sup>(5)</sup>	06/20/2016	Common Stock	313

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wood Mark C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			VP, Human Resources	

## Signatures

/s/ G. Eric Davis,  
Attorney-in-Fact

10/23/2007

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.

(2) Options vested 6/48ths on 11/3/2004 and 1/48th on the 3rd of each month thereafter.

(3) Options vested 6/48ths on 7/7/2005 and 1/48th on the 7th of each month thereafter.

(4) Options vested 6/48ths on 7/6/2006 and 1/48th on the 6th of each month thereafter.

(5) Options vested 6/48ths on 12/21/2006 and 1/48th on the 21st of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.